Follow-Up After — Stopping Targeted Therapy

Not necessarily, and your oncologist will use careful language about this. Stopping is possible when the disease has reached a very deep level of response and stayed there long enough that the risk of early return is considered low. That is different from a cure, and it is why monitoring continues. The term your team may use is treatment-free remission — a sustained period off medication with the disease under control, not a declaration that it is gone.

Usually quickly. If monitoring detects molecular relapse — disease returning in the blood — your team will contact you and restart treatment without waiting for symptoms to appear. In most cases, targeted therapy that worked before works again after restarting, and the response tends to return within weeks to months. The monitoring schedule is designed to catch this early enough that restarting remains a straightforward decision.

The schedule varies by cancer type and your oncologist's assessment — there is no single answer that applies to everyone. In general, tests are more frequent in the first months after stopping and may space out if results stay stable. Ask your oncologist specifically: how often, what test, and what result would prompt them to call you rather than wait for the next scheduled appointment. Having those answers written down helps.

No, and doing so carries real risk. Stopping without a plan means stopping without the monitoring that makes treatment-free remission a managed process. The timing of the decision, the schedule of tests, and the threshold for restarting are all part of what makes it safe. If you want to stop — because of side effects, cost, or simply because you are tired of the treatment — tell your oncologist directly. That is a conversation worth having openly, and there may be more options than you expect.

Many people do. Some targeted therapies cause fatigue, skin changes, gut effects, or other side effects that ease after stopping, and many people feel physically better in the months that follow. Many also notice anxiety about whether the disease will return — that is a normal response to a genuinely uncertain situation, not a sign something is wrong. If the worry is persistent or significant, mention it at your next appointment. Psychological support is part of survivorship care.

Molecular relapse — disease returning — usually shows up in a test before any symptoms appear, which is why the monitoring is there. That said, tell your team about any symptom that resembles the ones that led to your original diagnosis, any new lump or swelling, unusual or unexplained fatigue, or anything that does not settle within a week or two. You know your body. The monitoring does not replace your own awareness.